DK3386531T3 - Anvendelse af c-type natriuretiske peptidvarianter til behandling af osteoarthritis - Google Patents

Anvendelse af c-type natriuretiske peptidvarianter til behandling af osteoarthritis Download PDF

Info

Publication number
DK3386531T3
DK3386531T3 DK16852866.9T DK16852866T DK3386531T3 DK 3386531 T3 DK3386531 T3 DK 3386531T3 DK 16852866 T DK16852866 T DK 16852866T DK 3386531 T3 DK3386531 T3 DK 3386531T3
Authority
DK
Denmark
Prior art keywords
osteoarthritis
treatment
natriuretic peptide
type natriuretic
peptide variants
Prior art date
Application number
DK16852866.9T
Other languages
Danish (da)
English (en)
Inventor
Charles A O'neill
Todd M Oppeneer
Jason K Pinkstaff
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Application granted granted Critical
Publication of DK3386531T3 publication Critical patent/DK3386531T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2242Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK16852866.9T 2015-12-08 2016-12-08 Anvendelse af c-type natriuretiske peptidvarianter til behandling af osteoarthritis DK3386531T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562264682P 2015-12-08 2015-12-08
PCT/US2016/065520 WO2017100400A2 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis

Publications (1)

Publication Number Publication Date
DK3386531T3 true DK3386531T3 (da) 2022-01-03

Family

ID=59013378

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16852866.9T DK3386531T3 (da) 2015-12-08 2016-12-08 Anvendelse af c-type natriuretiske peptidvarianter til behandling af osteoarthritis

Country Status (17)

Country Link
US (2) US11202819B2 (cg-RX-API-DMAC7.html)
EP (2) EP4019038A3 (cg-RX-API-DMAC7.html)
JP (1) JP7104625B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180088459A (cg-RX-API-DMAC7.html)
CN (1) CN108697766A (cg-RX-API-DMAC7.html)
AU (2) AU2016365751B2 (cg-RX-API-DMAC7.html)
CA (1) CA3007315A1 (cg-RX-API-DMAC7.html)
DK (1) DK3386531T3 (cg-RX-API-DMAC7.html)
ES (1) ES2901769T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211908T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057083T2 (cg-RX-API-DMAC7.html)
IL (1) IL259690B2 (cg-RX-API-DMAC7.html)
MX (1) MX2018006986A (cg-RX-API-DMAC7.html)
PL (1) PL3386531T3 (cg-RX-API-DMAC7.html)
PT (1) PT3386531T (cg-RX-API-DMAC7.html)
RU (1) RU2759679C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017100400A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389511B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
IL318754A (en) 2016-01-08 2025-04-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
EP3400021A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
JP6968802B2 (ja) 2016-01-08 2021-11-17 アセンディス ファーマ グロース ディスオーダーズ エー/エス 環部分にキャリア結合を有するcnpプロドラッグ
MY195190A (en) 2016-01-08 2023-01-11 Ascendis Pharma Growth Disorders As Controlled-Release Cnp Agonists With Increased Nep Stability
US10835578B2 (en) 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
LT3518930T (lt) 2016-09-29 2023-05-10 Ascendis Pharma Growth Disorders A/S Kompleksinė terapija su kontroliuojamo išskyrimo cnp agonistais
US20210228497A1 (en) * 2018-04-27 2021-07-29 Remy Biosciences, Inc. New Medical Devices, Delivery Vehicles and Manufacturing Thereof
KR102893903B1 (ko) * 2019-02-11 2025-12-01 아센디스 파마 그로우쓰 디스오더스 에이/에스 Cnp 접합체의 건조 약학 제제
CN116635027A (zh) * 2020-11-25 2023-08-22 普罗林科斯有限责任公司 C-利钠肽的延长释放水凝胶偶联物
EP4337957A1 (en) * 2021-05-11 2024-03-20 Texas Tech University System Targeted selenium conjugates as countermeasures for pathogenic viruses and cells
AU2022407450A1 (en) * 2021-12-07 2024-07-11 Biomarin Pharmaceutical Inc. CNP Therapy
JP2025521254A (ja) 2022-11-02 2025-07-08 ノヴォ ノルディスク アー/エス Cnp化合物
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
KR20250098109A (ko) * 2023-12-21 2025-07-01 주식회사 펩트론 나트륨이뇨 펩타이드 유사체 및 이의 용도
CN117801123B (zh) * 2024-02-29 2024-05-03 天津凯莱英生物科技有限公司 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Cnp類似体ペプチド
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
CA2561530C (en) 2004-03-31 2014-04-22 Kazuwa Nakao Therapeutic or prophylactic agent for arthritis
EP3446711A1 (en) * 2004-03-31 2019-02-27 Kazuwa Nakao Composition for increasing body height
CA2705603A1 (en) 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
EP4029512A1 (en) * 2009-05-20 2022-07-20 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
WO2012088608A1 (en) * 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof

Also Published As

Publication number Publication date
PL3386531T3 (pl) 2022-02-28
PT3386531T (pt) 2021-12-29
RU2018124600A (ru) 2020-01-13
EP4019038A2 (en) 2022-06-29
CA3007315A1 (en) 2017-06-15
MX2018006986A (es) 2018-09-05
US20220160836A1 (en) 2022-05-26
EP3386531B1 (en) 2021-10-13
IL259690B (en) 2022-10-01
IL259690A (en) 2018-07-31
RU2021132347A (ru) 2022-03-24
CN108697766A (zh) 2018-10-23
WO2017100400A3 (en) 2017-10-26
RU2759679C2 (ru) 2021-11-16
EP4019038A3 (en) 2022-09-28
US20190247467A1 (en) 2019-08-15
EP3386531A2 (en) 2018-10-17
HRP20211908T1 (hr) 2022-03-04
JP7104625B2 (ja) 2022-07-21
RU2018124600A3 (cg-RX-API-DMAC7.html) 2020-01-13
US12214015B2 (en) 2025-02-04
AU2024201852A1 (en) 2024-04-11
HUE057083T2 (hu) 2022-04-28
KR20180088459A (ko) 2018-08-03
AU2016365751A1 (en) 2018-06-21
IL259690B2 (en) 2023-02-01
US11202819B2 (en) 2021-12-21
WO2017100400A2 (en) 2017-06-15
AU2016365751B2 (en) 2023-12-21
ES2901769T3 (es) 2022-03-23
JP2019505486A (ja) 2019-02-28

Similar Documents

Publication Publication Date Title
DK3386531T3 (da) Anvendelse af c-type natriuretiske peptidvarianter til behandling af osteoarthritis
IL268920A (en) Peptide vaccines
DK3328416T5 (da) Anvendelse af natriuretske peptidvarianter af c-typen til behandling af skeletdysplasi
IL253591B (en) Ultrasonic evaporation component
EP3362556C0 (en) POLYPEPTIDE VARIANTS
DK3368101T3 (da) Autoinjektor til engangsbrug
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
PL3512642T3 (pl) Rozwiązanie bezmłotkowe
UA32259S (uk) Розприскувач
DK3524255T3 (da) Sammensætning til behandling af acne
EP3954468C0 (de) Spritzpistole
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
EP3442990A4 (en) CHIRALE PEPTIDE
MA43397A (fr) Pyroglutamate de vortioxetine
DK3618845T3 (da) Peptider til behandling af diabetes
DK3795591T5 (da) Cys80-konjugerede immunoglobuliner
DK3442558T3 (da) Bmp-7-afledte peptider til anvendelse i behandlingen af osteoartritis
DK3286209T3 (da) Fremgangsmåde til fremstilling af gonadotrophin
DK3265110T3 (da) Peptider til inhibering af angiogenese
UA32541S (uk) Бак розприскувача